MAKE THE MOVE TO APRISO
APRISO features the INTELLICOR® delayed- and extended-release delivery system and helps keep adult patients with ulcerative colitis (UC) in remission for up to 6 months.1
While the mechanism of action is unknown, mesalamine may decrease inflammation in the colon by blocking production of arachidonic acid metabolites.1
APRISO has been evaluated in two 6-month placebo-controlled trials, and for up to 24 months in an open-label extension study.1,2
APRISO is contraindicated in patients with hypersensitivity to salicylates, aminosalicylates, or any of the components in APRISO capsules.
Proven Efficacy
- In clinical studies, ~7 of 10 patients in the intent-to-treat population maintained remission for up to 6 months with APRISO, compared with ~5.5 of 10 placebo patients1
Long-term Safety Profile
- APRISO has a well-established safety profile from a 6‑month controlled, and a 24‑month open‑label, trial. The efficacy of APRISO for treating UC beyond 6 months has not been established1,2
- Caution should be exercised when administering APRISO to patients with liver disease, known renal dysfunction or a history of renal disease
- The most common adverse events (≥3%) of APRISO-treated patients were headache, diarrhea, abdominal pain upper, nausea, nasopharyngitis, influenza-like illness, and sinusitis
Once Daily
- The recommended daily dosage is 4 APRISO 0.375-g capsules taken once daily (1.5 g/day) in the morning with or without food1